Organon & Co. Earnings Recaps
Q3 2025
Nov 11, 2025
Organon reported third-quarter 2025 revenue of $1.6 billion with an adjusted EBITDA of $518 million, despite ongoing challenges related to improper sales practices for its Nexplanon product.
Key takeaways
- Third-quarter revenue of $1.6 billion represents steady demand, reflecting the resilience of the product portfolio.
- Adjusted EBITDA margin improved to 32.3%, indicating effective cost management despite operational hurdles.
- An internal investigation into sales practices concluded with limited revenue impact and no need for financial restatements.
- New leadership has been appointed to oversee remediation efforts, ensuring compliance and operational excellence moving forward.
- The company remains committed to its strategic priorities of deleveraging and revenue growth amid ongoing changes in management.